BMS-986525OPDIVO 10 mg/mL concentrate for solution for infusion.
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Type, frequency, and severity of side effects.
Endpoint detail
How BMS-986525 behaves in the body alone and in combination with nivolumab;, How disease responds to BMS-986525 alone or in combination with nivolumab.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.